All Updates

All Updates

icon
Filter
Earnings/results
Personalis misses Q4 2022 analyst consensus; revenue dips and losses widen
Precision Medicine
Feb 22, 2023
This week:
Product updates
Meta introduces Meta Credits digital currency for Horizon Worlds
Metaverse Platforms
Today
Product updates
Liquid AI launches STAR framework for AI model architecture optimization
Foundation Models
Today
Funding
9fin raises USD 50 million in Series B funding to expand US operations
Capital Markets Tech
Yesterday
Partnerships
Shastic partners with MeridianLink to provide AI workflow automation for financial institutions
Workflow Automation Platforms
Yesterday
Funding
KisoJi Biotechnology raises CAD 41 million to develop oncology candidate
AI Drug Discovery
Yesterday
M&A
Deel acquires UK money transfer startup Atlantic Money for undisclosed sum
Remote Work Infrastructure
Yesterday
Funding
Acorai raises EUR 4.2 million in funding to advance clinical studies
Next-gen Medical Devices
Yesterday
Product updates
Bosch announces Light Drive, an AR solution for all-day smart glasses
Extended Reality
Yesterday
Product updates
Partnerships
Vuzix expands OSHA collaboration; launches upgraded M400 AR smart glasses
Extended Reality
Yesterday
Product updates
StrikerVR launches pre-orders for consumer-facing Mavrik haptic VR gun
Extended Reality
Yesterday
Precision Medicine

Precision Medicine

Feb 22, 2023

Personalis misses Q4 2022 analyst consensus; revenue dips and losses widen

Earnings/results

  • Genomic testing company Personalis reported a net loss per share of USD 0.67 in Q4 2022, missing analysts’ expectations by 4%. The firm’s net losses for the quarter and full year widened by 54% YoY and 74% YoY, respectively, as Personalis amid a decline in revenue and higher operating expenses.

  • The completion of all its outstanding task orders from the US Department of Veterans Affairs Million Veterans Program (VA MVP) led to a 19% YoY decline in total revenue in Q4 2022 to USD 16.7 million and also affected revenue for the full year, which slipped 24% YoY to USD 65 million.

  • The gross margin for Q4 2022 also declined significantly to 14% from 39% due to a decline in revenue despite a shift in revenue mix to high-margin customers. Operating expenses increased on the back of higher R&D costs (up 14% YoY), and selling, general, and administrative expenses (up 30% YoY). 

  • During Q4 2022, the company announced a continuing partnership with Moderna to provide genomic testing for the latter's investigational personalized cancer vaccine's upcoming clinical studies and initiated a research collaboration with University Medical Center Hamburg-Eppendorf to use its' NeXT Personal to track tumor response to immunotherapy (IO) in melanoma patients.

  • In terms of its 2023 guidance, Personalis expects revenue in the range of USD 68–72 million, implying an increase of 5%–11%. The firm projects a net loss of USD 103 million, down from USD 113 million in 2022 due to savings from layoffs which is partially offset by investments in clinical evidence generation and non-cash depreciation expense for the new facility. It expects cash usage of USD 75 million, down from USD 119 million in 2022.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.